Paget's Disease of the Vulva Withdrawn Phase 2 Trials for Trastuzumab (DB00072)

Also known as: Paget disease of vulva

IndicationStatusPhase
DBCOND0053815 (Paget's Disease of the Vulva)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01427244Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's DiseaseTreatment